Clinical trials: Meal Time
Type 1 Diabetes
A Study to Compare ORMD-0801 Once Daily to ORMD-0801 Three Times Daily in Subjects With Type 1 Diabetes
This study is a Phase 2 randomized, crossover study comparing ORMD-0801 given QD versus TID in subjects with T1D. Subjects with T1D will have a screening visit (Visit 1) during which they will be required to review and sign the…
- Trial name
- NCT04150107
- Testing
- ORMD-0801 Treatment A, ORMD-0801 Treatment B
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oramed, Ltd.
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes
This trial is conducted in Europe. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir, insulin aspart and biphasic insulin aspart 30, when added to…
- Trial name
- 4T (NCT00184600)
- Testing
- biphasic insulin aspart, insulin detemir, insulin aspart
- Where
- 63 sites in Ireland, United Kingdom
- Volunteers
- 708 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.
- Trial name
- ONWARDS 4 (NCT04880850)
- Testing
- Insulin icodec, Insulin glargine, Insulin aspart
- Where
- 116 sites in United States, Belgium and 7 more
- Volunteers
- 582 people
- Sponsor
- Novo Nordisk A/S
Alzheimer's Disease and Related Dementias
OPTIMAL in NH Residents With Dementia
The purpose of this study is to develop and refine OPTIMAL and evaluate its feasibility, fidelity, and usefulness. The OPTIMAL is designed to teach staff to effectively engage residents in eating using individualized…
- Trial name
- NCT05255068
- Testing
- OPTIMAL
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- University of Iowa
Obesity
Effectiveness of Differing Levels of Support for Family Mealtimes on Obesity Prevention Among Head Start Preschools
Socioeconomic disparities in early childhood place low-income children at 1.5 to 2 times higher risk for obesity compared to middle- to upper-income children.
- Trial name
- SimplyDinner (NCT02487251)
- Testing
- Mealtime Supports, Usual Exposure
- Where
- 4 sites in United States
- Volunteers
- 810 people, healthy volunteers welcome
- Sponsor
- Michigan State University
Type 1 Diabetes
Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes
A phase 4 study evaluating the efficacy of mealtime control with Afrezza in combination with an automated insulin pump or insulin degludec in adult subjects with type 1 diabetes
- Trial name
- ABC (NCT05243628)
- Testing
- Afrezza (insulin human) Inhalation Powder, insulin degludec, Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 2
A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics
This study will look into insulin sensitivity (how the body responds to insulin) and effects of meals on type 2 diabetics comparing insulin peglispro to insulin glargine.
- Trial name
- NCT02197520
- Testing
- Insulin Peglispro, Insulin Glargine, Insulin Lispro
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Type2 Diabetes
Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients
To examine the effects of adding prandial Afrezza inhaled insulin to patients with type 2 diabetes who are not controlled after at least 6 months of other diabetes treatments including oral agents, basal insulin, or GLP-1 use.
- Trial name
- NCT03324776
- Testing
- Afrezza Inhalant Product
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Model Clinical Research LLC
Obesity
Healthy Home Offerings Via the Mealtime Environment (HOME) Plus
The goal of the proposed project is to see if an innovative family-based intervention can reduce childhood obesity by actively engaging the whole family in promoting healthy behaviors in the home.
- Trial name
- NCT01538615
- Testing
- HOME Plus intervention
- Where
- United States
- Volunteers
- 413 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Type 2 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Primary Objective: To compare the efficacy of insulin glargine new formulation and Lantus in terms of change in HbA1c from baseline to endpoint (scheduled month 6) in adult participants with type 2 diabetes mellitus Secondary…
- Trial name
- EDITION I (NCT01499082)
- Testing
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Where
- 193 sites in United States, Canada and 11 more
- Volunteers
- 807 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1 Diabetes
A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) is a challenging medical disorder, especially in children and adolescents. In order to prevent the chronic complications of hyperglycemia, the maintenance of near-normal glycemic control must be…
- Trial name
- NCT04157738
- Testing
- Rapid-Acting Insulin, Long acting insulin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Emory University
Healthy
Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy Volunteers
To evaluate the effect of food on the pharmacokinetics of BI 409306 and to investigate the pharmacokinetics of BI 409306 when given at bed time.
- Trial name
- NCT02222168
- Testing
- BI 409306
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity, Childhood, Physical Activity
New Ulm at HOME (Healthy Offerings Via the Mealtime Environment), NU-HOME
The goal of the proposed project is to see if an innovative family-based intervention can reduce childhood obesity by actively engaging the whole family in promoting healthy behaviors in the home.
- Conditions
- Obesity, Childhood, Physical Activity, Food Intake, Rural Health
- Trial name
- NU-HOME (NCT02973815)
- Testing
- NU-HOME Intervention
- Where
- United States
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Type 1 Diabetes
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in combination with mealtime insulin lispro in adult Chinese participants with Type 1 Diabetes Mellitus (T1DM).
- Trial name
- NCT03338023
- Testing
- LY2963016, Lantus®, Insulin Lispro
- Where
- 20 sites in China
- Volunteers
- 272 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes
This trial is conducted in Europe. The purpose of this trial is to investigate if there is any change in the mechanism of energy expenditure (i.e.
- Trial name
- NCT00509925
- Testing
- insulin detemir, insulin NPH, insulin aspart
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of insulin degludec/insulin aspart once daily plus insulin aspart for the remaining meals in…
- Trial name
- NCT01835431
- Testing
- insulin degludec/insulin aspart, insulin aspart, insulin detemir
- Where
- 73 sites in United States, Belgium and 13 more
- Volunteers
- 362 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
This study compares insulin icodec (a new insulin) to insulin degludec (an insulin already available on the market) in people with type 1 diabetes.
- Trial name
- ONWARDS 6 (NCT04848480)
- Testing
- insulin icodec, insulin degludec, insulin aspart
- Where
- 130 sites in United States, Austria and 10 more
- Volunteers
- 582 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin
Primary Objective: To compare the glucose control during treatment with a new formulation of insulin glargine and Lantus in adult participants with type 1 diabetes mellitus Secondary Objectives: To compare a new formulation of…
- Trial name
- NCT01658579
- Testing
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment
This trial is conducted in Europe. The aim of this clinical trial is to compare the change in trunk fat mass, assessed by Double Energy X-ray Absorptiometry (DEXA) after 26 weeks of treatment with insulin detemir or insulin NPH…
- Trial name
- NCT00795600
- Testing
- insulin detemir, insulin NPH
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Study in Adults With Type 1 Diabetes
The purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus when taken once daily in combination with insulin lispro before meals three times a day.
- Trial name
- ELEMENT 1 (NCT01421147)
- Testing
- LY2963016, Lantus, Insulin Lispro
- Where
- 52 sites in United States, Belgium and 7 more
- Volunteers
- 536 people
- Sponsor
- Eli Lilly and Company